Overview
Cambridge-based neurotechnology company developing non-invasive neuromodulation therapeutics for neurodegenerative diseases, with Spectris AD as its lead Alzheimer's disease program.
Unlock the full profileGet the complete company dossier
This public view only shows an extract. Open the full profile to access the complete company intelligence record, including the full write-up and structured research details.